Noribogainalog

Noribogainalog
Clinical data
Other namesNor-IBG; 9-Hydroxyibogaminalog; GATC-021; GATC021
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • 3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indol-9-ol
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H16N2O
Molar mass216.284 g·mol−1
3D model (JSmol)
  • CN1CCC2=C(CC1)NC3=C2C=C(C=C3)O
  • InChI=1S/C13H16N2O/c1-15-6-4-10-11-8-9(16)2-3-12(11)14-13(10)5-7-15/h2-3,8,14,16H,4-7H2,1H3
  • Key:OOROJSRWMMKEQK-UHFFFAOYSA-N

Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog or as GATC-021, is a drug of the ibogalog family related to noribogaine.[1][2][3] It is a simplified analogue of noribogaine.[1][2]

Pharmacology

Pharmacodynamics

Noribogainalog acts as a potent serotonin 5-HT2A receptor partial agonist (EC50Tooltip half-maximal effective concentration ≈ 90 nM; EmaxTooltip maximal efficacy = 35–45%).[2][3] It is also a partial agonist of the serotonin 5-HT6 receptor (Emax = 29%), whereas it is not an agonist of the serotonin 5-HT2B and 5-HT7 receptors.[3] The drug additionally has activity as a dopamine transporter (DAT) chaperone.[4]

Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures.[2] However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin.[2] In addition, a subsequent study found that the highest assessed dose produced significant hypolocomotion and that the drug also reduced fentanyl self-administration.[3]

Pharmacokinetics

Noribogainalog shows relatively low expected blood–brain barrier permeability.[2]

Chemistry

Synthesis

The chemical synthesis of noribogainalog has been described.[3]

Analogues

Analogues of noribogainalog include catharanthalog, ibogainalog, ibogaminalog, PNU-22394, tabernanthalog, 4-allyl-6-oxa-noribogainalog, and noribogaine, among others.

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.[1]

See also

References

  1. ^ a b c Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. (January 2021). "A non-hallucinogenic psychedelic analogue with therapeutic potential". Nature. 589 (7842): 474–479. Bibcode:2021Natur.589..474C. doi:10.1038/s41586-020-3008-z. PMC 7874389. PMID 33299186.
  2. ^ a b c d e f Arias HR, Micheli L, Jensen AA, Galant S, Vandermoere F, Venturi D, et al. (March 2025). "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors". Biomedicine & Pharmacotherapy. 184 117887. doi:10.1016/j.biopha.2025.117887. hdl:2158/1423286. PMID 39938347.
  3. ^ a b c d e Lallai V, Kho S, Martin AC, Fowler JP, Roach ML, Wang K, et al. (April 2026). "AI-derived therapeutic development of a serotonin receptor-targeting drug for the treatment of opioid use disorder". Proc Natl Acad Sci U S A. 123 (15) e2516807123. doi:10.1073/pnas.2516807123. PMID 41941629.
  4. ^ Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, et al. (2022). "Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones". Frontiers in Cellular Neuroscience. 16 832536. doi:10.3389/fncel.2022.832536. PMC 9124866. PMID 35614973.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.